TAFINLAR (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
TAFINLAR
Date registered
Evaluation commenced
Decision date
Approval time
202 working days (255)
Active ingredients
dabrafenib
Registration type
EOI
Indication
Anaplastic thyroid cancer (ATC)
TAFINLAR (capsules) in combination with trametinib is now also indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600 mutation and with no satisfactory locoregional treatment options.
Non-small cell lung cancer (NSCLC)
TAFINLAR in combination with trametinib is now also indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.